SCHEMBL1768156

SCHEMBL1768156

O=C(N[C@@H](CSSC[C@H](NC(=O)c1ccccc1)C(=O)O)C(=O)O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACE P12821 2/20 0.51
PTPN1 P18031 2/20 0.50
SLC1A2 P43004 1/20 0.49
IDO1 P14902 1/20 0.48
CA2 P00918 6/20 0.48
CA1 P00915 3/20 0.48
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CRHBP P24387 1/20 0.47
KMT2A Q03164 1/20 0.47
CRHR2 Q13324 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 1/20 0.47
HSD17B10 Q99714 1/20 0.47
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2419579 1.00 ACE (0.51) ACEPTPN1SLC1A2IDO1CA2
SCHEMBL6411060 1.00 ACE (0.51) ACEPTPN1SLC1A2IDO1CA2
SCHEMBL8787239 0.91 SLC1A2 (0.49) ACEPTPN1SLC1A2CA2CA1
SCHEMBL14671279 0.88 ACE (0.55) ACEPTPN1CA2CA1KMT2A
SCHEMBL4954825 0.88 FNTA (0.54) ACEPTPN1CA2CA1MEN1
SCHEMBL12020054 0.87 CYP26A1 (0.48) MEN1KMT2ATDP1LMNAHSD17B10
SCHEMBL12019153 0.86 ALDH1A1 (0.51) MEN1ALDH1A1CRHBPKMT2ACRHR2
SCHEMBL2806082 0.85 ALDH1A1 (0.50) ACEPTPN1SLC1A2IDO1CA2
SCHEMBL10805856 0.85 PTPN1 (0.50) ACEPTPN1SLC1A2IDO1CA2
SCHEMBL2806085 0.85 ALDH1A1 (0.50) ACEPTPN1SLC1A2IDO1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117137860-A Preparation and application of isoniazid and amino acid-based in-situ hydrogel material 赣南师范大学 2023-12-01 CN claimed
CN-110527662-B Injection type cystine micromolecule gel material and application thereof 赣南师范大学 2022-11-04 CN claimed
US-9410000-B2 Method to produce hyaluronic acid functionalized derivatives and formation of hydrogels UNIVERSITA' DEGLI STUDI DI PALERMO (IT) 2016-08-09 US claimed
US-9180195-B2 Controlled release gels NANO FIBER MATRICES B.V. (NL) 2015-11-10 US claimed
US-20150183891-A1 METHOD TO PRODUCE HYALURONIC ACID FUNCTIONALIZED DERIVATIVES AND FORMATION OF HYDROGELS UNIVERSITA' DEGLI STUDI DI PALERMO (IT) 2015-07-02 US claimed
US-8858999-B2 Method to produce hyaluronic acid functionalized derivatives and formation of hydrogels thereof UNIVERSITA' DEGLI STUDI DI PALERMO (IT) 2014-10-14 US claimed
EP-2370474-B1 METHOD TO PRODUCE HYALURONIC ACID FUNCTIONALIZED DERIVATIVES AND FORMATION OF HYDROGELS THEREOF UNIV PALERMO (IT) 2012-10-24 EP claimed
US-20110236486-A1 METHOD TO PRODUCE HYALURONIC ACID FUNCTIONALIZED DERIVATIVES AND FORMATION OF HYDROGELS THEREOF UNIVERSITA' DEGLI STUDI DI PALERMO (IT) 2011-09-29 US claimed
EP-1631261-B1 PRODUCTION OF SMALL PARTICLES APPLIED NANOSYSTEMS BV (NL) 2009-07-15 EP claimed
US-20090169498-A1 Controlled Release Gels NANO FIBER MATRICES B.V. (NL) 2009-07-02 US claimed
EP-1968638-A1 CONTROLLED RELEASE GELS Applied NanoSystems B.V. (NL) 2008-09-17 EP claimed
WO-2007073180-A1 CONTROLLED RELEASE GELS APPLIED NANOSYSTEMS B.V. (NL) 2007-06-28 WO claimed
EP-1800694-A1 Controlled release gels Applied NanoSystems B.V. (NL) 2007-06-27 EP claimed
US-12584080-B2 Gel-like shaped body for fragrancing textiles during the washing process HENKEL AG & CO. KGAA (DE) 2026-03-24 US disclosed
EP-4508181-B1 METHOD FOR MANUFACTURING A DETERGENT PORTION UNIT HENKEL AG & CO KGAA (DE) 2026-03-11 EP disclosed
EP-4508180-B1 METHOD FOR MANUFACTURING A DETERGENT PORTION UNIT HENKEL AG & CO KGAA (DE) 2026-01-14 EP disclosed
US-5204248-A Enzymatic reduction of corresponding oxo derivative; intermediate for diltiazem TANABE SEIYAKU CO., LTD. (JP) 1993-04-20 US disclosed
US-5081240-A PROCESS FOR THE PREPARATION OF BENZOTHIAZEPIN-ONE DERIVATIVES SANOFI (FR) 1992-01-14 US disclosed
EP-0447938-A1 Process for preparing 2-halogeno-3-hydroxy-3-phenyl-propionic acid ester compounds TANABE SEIYAKU CO., LTD. (JP) 1991-09-25 EP disclosed
EP-0409712-A1 Process for the preparation of a stereoisomer of glycidyl esters, intermediates and process for the preparation of benzothiazepinone derivatives ELF SANOFI (FR) 1991-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584080-B2 Gel-like shaped body for fragrancing textiles during the washing process ADH1C, AKR1C3, AKR1C4 ACE 3137/4885PTPN1 2294/4885SLC1A2 4753/4885
US-20090169498-A1 Controlled Release Gels PGA5, SUCLG1, CDC37 ACE 3304/4885PTPN1 2257/4885SLC1A2 4675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.